Empagliflozin 12.5 MG + Metformin HCl 500 MG Tablets – Xempia M 12.5/500

Empagliflozin 12.5 MG + Metformin HCl 500 MG Tablets – Dual action formula to manage type 2 diabetes with CVD benefits.

Empagliflozin 12.5mg + Metformin HCl 500mg is a dual-action oral anti-diabetic medication that combines Empagliflozin (SGLT2 inhibitor) and Metformin (biguanide) to effectively manage Type 2 Diabetes Mellitus (T2DM).
✅Empagliflozin reduces blood sugar levels by preventing glucose reabsorption in the kidneys, promoting glucose excretion through urine. Additionally, it supports weight management and provides cardiovascular benefits.
✅Metformin reduces hepatic glucose production, improving insulin sensitivity, and enhancing glucose uptake in peripheral tissues.
This combination ensures comprehensive glycemic control while providing additional metabolic and cardiovascular advantages.

Recommended by Specialists:
✅Diabetologists – For effective glycemic control in Type 2 Diabetes Mellitus.
✅Cardiologists – To lower cardiovascular risks in diabetic patients, particularly those at risk of heart failure.
✅Nephrologists – To protect kidney function and reduce the progression of diabetic nephropathy.

Key Benefits of Empagliflozin 12.5 MG + Metformin HCl 500 MG Tablets – Xempia M 12.5/500:
✅Dual-Action Therapy – Empagliflozin and Metformin work together for optimal blood sugar control.
✅Supports Weight & Cardiovascular Health – Empagliflozin aids in weight reduction and offers cardiovascular protection.
✅Improved Patient Compliance – Lower Metformin dose reduces gastrointestinal side effects, ensuring better treatment adherence.

Indications:
✅Type 2 Diabetes Mellitus – For improved glycemic control.
✅Patients with Uncontrolled Blood Sugar – Especially those requiring an additional agent beyond Metformin alone.
✅Cardiovascular Risk Reduction – In diabetic patients with existing heart disease or risk factors.